SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2022 Earnings Call Transcript

Jurgi Camblong: Maybe, Marta, just to end on your question regarding the territories, as you know, SOPHiA sells to local partners. So, we’re very proud to announce the partnership with Qiagen this quarter. Actually, Qiagen is going to combine their QIAseq consumables with SOPHiA DDM. And so, if you see where Qiagen is present as well, which is even broader than SOPHiA, this can give you a sense of where we expect to grow as well as partners. And beyond that, Microsoft, right? So, we have a decent, I would say, sales team, but obviously not a sales team which is as broad and as big as the one of Microsoft. And so, there, in particular, in the US, we’re making a strong focus on expanding our market penetration. So, the landing of SOPHiA DDM together with Microsoft.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Dr. Jurgi Camblong along for any closing remarks.

Jurgi Camblong: Yes, thank you all for joining us in the call today. We’re actually very excited with what SOPHiA has been able to achieve in overall 2022 and even the acceleration in Q4 2022. So stay tuned. We will be today at the Cowen Healthcare Conference, next week in Miami at the Barclays conference. And we’re going to report our Q1 numbers in May. And we will, while we are making progress as well, keep you updated on anything that is important and the good traction that we’re adding overall around the world. Thank you for the call today. Bye now.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.